Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | POLB | P06746 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 3/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
| ▸ | F2 | P00734 | 1/20 | 0.38 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.38 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.38 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.37 |
| ▸ | KDR | P35968 | 1/20 | 0.37 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15498679 | 0.80 | PDE4D (0.50) | SMYD3ALDH1A1HSD17B10KDM4EPOLB | |
| SCHEMBL23382047 | 0.79 | HSD17B10 (0.54) | NPSR1MAPK1KDM4CALDH1A1HSD17B10 | |
| SCHEMBL13941182 | 0.78 | NPSR1 (0.41) | NPSR1MAPK1KDM4CALDH1A1HSD17B10 | |
| SCHEMBL29217303 | 0.78 | NPSR1 (0.41) | NPSR1MAPK1KDM4CALDH1A1HSD17B10 | |
| SCHEMBL2944190 | 0.78 | NPSR1 (0.41) | NPSR1MAPK1KDM4CALDH1A1HSD17B10 | |
| SCHEMBL2237645 | 0.78 | TSHR (0.42) | SMYD3NPSR1MAPK1KDM4CALDH1A1 | |
| SCHEMBL18572717 | 0.77 | NPSR1 (0.60) | NPSR1MAPK1ALDH1A1HSD17B10LMNA | |
| SCHEMBL31237156 | 0.75 | NPSR1 (0.39) | NPSR1MAPK1KDM4CALDH1A1HSD17B10 | |
| SCHEMBL26422041 | 0.75 | HSD17B10 (0.42) | NPSR1MAPK1KDM4CALDH1A1HSD17B10 | |
| SCHEMBL2826789 | 0.74 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3856179-B1 | MONOACYLGLYCEROL LIPASE MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2026-05-13 | — | — | EP | disclosed |
| US-20240327410-A1 | Monoacylglycerol Lipase Modulators | JANSSEN PHARMACEUTICA NV (BE) | 2024-10-03 | — | — | US | disclosed |
| CN-113164458-B | Monoacylglycerol lipase modulators | 詹森药业有限公司 | 2024-09-13 | — | — | CN | disclosed |
| US-11993601-B2 | Monoacylglycerol lipase modulators | JANSSEN PHARMACEUTICA NV | 2024-05-28 | — | — | US | disclosed |
| US-20230373969-A1 | MK2 INHIBITORS AND USES THEREOF | XINTHERA, INC. | 2023-11-23 | — | — | US | disclosed |
| US-20230373969-A1 | MK2 INHIBITORS AND USES THEREOF | XINTHERA, INC. | 2023-11-23 | — | — | US | disclosed |
| US-20230265076-A1 | MK2 INHIBITORS AND USES THEREOF | XINTHERA, INC. | 2023-08-24 | — | — | US | disclosed |
| US-20230265076-A1 | MK2 INHIBITORS AND USES THEREOF | XINTHERA, INC. | 2023-08-24 | — | — | US | disclosed |
| US-20230242531-A1 | Monoacylglycerol Lipase Modulators | JANSSEN PHARMACEUTICA NV (BE) | 2023-08-03 | — | — | US | disclosed |
| US-11680056-B2 | MK2 inhibitors and uses thereof | XINTHERA, INC. (US) | 2023-06-20 | — | — | US | disclosed |
| US-11680056-B2 | MK2 inhibitors and uses thereof | XINTHERA, INC. (US) | 2023-06-20 | — | — | US | disclosed |
| US-11597728-B2 | Monoacylglycerol lipase modulators | JANSSEN PHARMACEUTICA NV (BE) | 2023-03-07 | — | — | US | disclosed |
| US-20220402892-A1 | MK2 INHIBITORS AND USES THEREOF | XINTHERA, INC. | 2022-12-22 | — | — | US | disclosed |
| US-20220315583-A1 | Monoacylglycerol Lipase Modulators | JANSSEN PHARMACEUTICA NV (BE) | 2022-10-06 | — | — | US | disclosed |
| CN-113164458-A | Monoacylglycerol lipase modulators | 詹森药业有限公司 | 2021-07-23 | — | — | CN | disclosed |
| WO-2020117759-A1 | SMALL MOLECULE DEGRADERS OF HELIOS AND METHODS OF USE | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2020-06-11 | — | — | WO | disclosed |
| US-20200102311-A1 | Monoacylglycerol Lipase Modulators | JANSSEN PHARMACEUTICA NV (BE) | 2020-04-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230242531-A1 | Monoacylglycerol Lipase Modulators | MGLL, LPL, PNLIP | SMYD3 3315/4885NPSR1 554/4885MAPK1 4069/4885 |
| US-20230373969-A1 | MK2 INHIBITORS AND USES THEREOF | MKNK2, ENPP2, MAPKAPK2 | SMYD3 3219/4885NPSR1 3861/4885MAPK1 178/4885 |
| US-11680056-B2 | MK2 inhibitors and uses thereof | MKNK2, ENPP2, MAPKAPK2 | SMYD3 3219/4885NPSR1 3861/4885MAPK1 178/4885 |
| US-20230265076-A1 | MK2 INHIBITORS AND USES THEREOF | MKNK2, ENPP2, MAPKAPK2 | SMYD3 3219/4885NPSR1 3861/4885MAPK1 178/4885 |
| US-20220402892-A1 | MK2 INHIBITORS AND USES THEREOF | MKNK2, ENPP2, MAPKAPK2 | SMYD3 2786/4885NPSR1 3875/4885MAPK1 244/4885 |
| US-11993601-B2 | Monoacylglycerol lipase modulators | MGLL, LPL, PNLIP | SMYD3 3315/4885NPSR1 554/4885MAPK1 4069/4885 |
| US-20200102311-A1 | Monoacylglycerol Lipase Modulators | MGLL, LPL, PNLIP | SMYD3 3315/4885NPSR1 554/4885MAPK1 4069/4885 |
| US-11597728-B2 | Monoacylglycerol lipase modulators | MGLL, LPL, PNLIP | SMYD3 3315/4885NPSR1 554/4885MAPK1 4069/4885 |
| US-20240327410-A1 | Monoacylglycerol Lipase Modulators | MGLL, LPL, PNLIP | SMYD3 3315/4885NPSR1 554/4885MAPK1 4069/4885 |
| US-20220315583-A1 | Monoacylglycerol Lipase Modulators | MGLL, LPL, PNLIP | SMYD3 3315/4885NPSR1 554/4885MAPK1 4069/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.